The h&xjynar+ effe&s of a new paretier@ formulation ,of nifedioine adminisiered by the intravenous (1. m$f) and @acoronary (ICZ) (0.1 and. O.? mg) route's tier? studied .In '30 patients with symptom&it5 ,aronary art&y disease undergoing c&&g-n&tic right-and M-sided cardiac catheterization. lntravetious nifedipine (I mg) reduced systemic vatiiar resistance by 34.% fp <O.O!), increased cardiac output by 28% (p <O.Ol) and de&ased mean arterial pressure by 10% (p <O.Oi). It had I&s eff&ct on peak positive dP/dl (-8% p <O.p25) and on peak yegative dP/dt (-15 % p <O.Oj). Coronary blood flow increased 20% (p 50.025). in contrast, IC,nifedipine (0.2 mg) increased coronary blood flow 46% (p <0.025), depye+ed .contractitity as assessed by peak positive dP/dt (-26% b <O.Ol) and prolonged diastolic relax&ion tirire. The Meet of 0.1 mg was similar but iesq pronounced. These data suggest that the primary therapeutic effect of nifedipine administered s$t&nicail* to.pritients tit rest results from an inchase ih.cororjary blood flow and, to a lesser extent, from afterload reduction; its myocardial de-, pri&sant effects are small, transient and masked by r&flex catecholamine release. IC nifdipine increas& coronary blood flciw, has a transient negaiive @tropic effect and prolongs relajtation. The relative limpdance of these myocardiai effects in preventing myocarbial ischemia is not known.
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(Am J Cardiol 1986;58: [25] [26] [27] [28] [29] [30] N ifedipine, a calcium-channel blocking drug, has negative inotropic and vasodilatory effects in vitro, but acts primarily as a vasodilator in vivo.*J It is effective in the treatment of angina pectoris dqe to coronary vasospasm3-5 or after exertion.6-8 Administered systemically, its efficacy in ameliorating pacing-and exercise-induced angina ha.+ beeri attributed to afterload reductiorQJv9J'J to increased coronary blood flowgJlvia a direct vasodilatory effect or by reducing extrinsic cqronary vascular compressive forces in diastolesJOY and to a direct myocardial effeqt.lz Administered by the intracoronary (ICI route, nifedipine increases coronary sinus flow, *l-l3 decreases myocardial oxygen consumption,13J4 relieires spontaneous or ergonovine-induced coronary artery spasm4 and prolongs regional shortening,ls thereby prolongin'g relaxation time. 16 Kaitenbach et all2 observed that the antianginal effect of IC nifedipine persisted for 10 minutes longer than its effect on hemodynamics and on coronary flow and, on that basis, suggested that intracoronary nifedipine has a direct myocardial effect. This study relates the direct myocardial effects of the drug administered by the IC route to changes in coronary blood flow in patients with ischemic disease, and compares these effects with those of nifedipine administered by the intravenous [IV) route.
blethdds Patierits: Ten patients (8 men, 2 women], 38 to 59 years old, who underwent diagnostic cardiac catheteriztitjon for symptomatic coronary artery disease were studied [ Table I ]. Mean ejection fraction was 63%. Nobe had valvular or congenital heart disease, unstable angina, second-or third-degree heart block, major systemic disorders or diabetes mellitus.
Protocol: Topical nitSate and P-blocker therapy were stopped 48 hours, and calcium-channel blocker therapy 72 hours before catheterization. After routine right-and left-sided cardiac catheterization and coronary arteriography, the baseline hemodynamic values were measured. They included heart rate, blood pressure, left ventricular pressure (4Fr or 5Fr Millar micro- manometer-tip catheter), electronically differentiated left ventricular dP/dt, pulmonary capillary wedge, pulmonary artery and right atria1 pressures, cardiac output (thermodilution, Swan-Ganz catheter) and coronary sinus flow (thermodilution, Wilton-Webster catheter through the left antecubital vein). Measurement of coronary blood flow remained stable: coronary flows measured before infusion of different doses were the same, and coronary flows at the end of a period of observation were the same as at the beginning (Tables 11, III were repeated. Then, 1 mg was infused by the IV route over 3 minutes; measurements were made at the end of infusion, at 1,3,5 minutes and every 5 minutes thereafter for 36 minutes. Evaluation of data: All phasic pressures were determined as the mean of 5 successive sinus beats over 1 respiratory cycle. Cardiac outputs represent the mean of 3 measurements. The value of a~ hemodynamic parameter was calculated as the absolute or percent difference between the baseline value and each subsequent value. The time constant of relaxation, 7, was derived from the best fit of a monoexponential to the time course of isovolumic left ventricular pressure decay.17J8 The correlation coefficients for these experimental fits were never less than 0.97. Statistical significance was determined using a Student t test on paired differences between the value of a hemodynamic variable at any time during the infusion and its baseline value.
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Results
Systemic effects of nifedipine (Tables II, III As assessed by systolic pressure-rate product, external cardiac work was reduced for at least 15 minutes after drug administration. Left ventricular end-diastolic pressure, peak positive and negative dP/dt and 7 hhanged little. In contrast, the systemic effects of IC nifedipine were h-d1 and short-lived.
Direct effects of lriifedipine (Tables II, III (7) +0.2 f 7.9 -9 f 37(6) -2 f 31 (6) fedipine increased coronary blood flow by only 20%; nonetheless, this occurred without a significant reduction in systolic pressure-rate product.
Discussion
Our data suggest that the antianginal effect of IV nifedipine results more from an increase in myocardial oxygen supply than from a reduction in myocardial oxygen consumption or in myocardial contractility. Despite the marked decrease in systemic vascular resistance, the reduction of mean arterial pressure was small. Reflex tachycardia, reflecting catecholamine release, precluded a marked and sustained reduction of systolic pressure-rate product, an adequate index of myocardial oxygen consumption that takes catecholamine effects into account.lg KochzO observed higher catecholamine levels among patients undergoing su- Data are expressed as the mean change from baseline f standard deviation. The number of patients evaluated is in parentheses unless the number is 10. * p <O.Ol; t p <0.025; t p <0.05 by paired t test. Abbreviations as in Table I. pine bicycle exercise after administration of nifedipine than among control subjects. Our data are in agreement with those of Schanzenbather et a1,13 who administered IV nifedipine to patients at rest, and with those of Specchia et al? who reported that the antianginal potency of nifedipine administered systemically to patients with exercise-induced angina was attributable almost entirely to an increase in coronary blood flow. However, our data are at variance with other reports. Engel,g Emanuelssonlo and their co-workers attributed the efficacy of nifedipine administered systemically to patients with pacing-induced angina both to afterload reduction and to increased myocardial perfusion. Moskowitz et al6 found that systemic nifedipine ameliorated exerciseinduced angina by reducing the double product at a given workload; however, myocardial oxygen supply was not measured. Kaltenbach blood flow, but also invoked a "direct myocardial influence" to explain the drug's antianginal effect. These differences may be explained by different doses and routes of drug administration, by the different levels of activity of the subjects or by different degrees of myocardial dysfunction.
The direct myocardial and coronary vascular effects of IC nifedipine help to rationalize the drug's transient antianginal effect. IC nifedipine depressed contractility, as evidenced by the decrease in peak positive dP/dt, which occurred despite an increase in heart rate; this was not attributable to the decrease in mean arterial pressure, since a larger and more sustained decrease in arterial pressure after IV nifedipine was not accompanied by a reduction of peak positive dP/dt of a similar magnitude or durationz* This observation is compatible with that of Serruys et a1,15 who noted prolongation of systolic shortening in the distribution of vein grafts after injection of nifedipine. Relaxation was prolonged, as observed by Serruys, 22 Roussead6 and their co-workers, probably because of drug-induced asynchronous myocardial contraction16 or to a direct myocardial effect on relaxation. Coronary blood flow was markedly increased in the absence of a significant change in double product. Although these effects explain a short-term antianginal effect observed by others, 13,15 they do not explain the prolonged antianginal efficacy of IC nifedipine in exercise-induced ischemia reported by Kaltenbach et a1.12 It is possible that autoregulatory mechanisms governing coronary blood flow mobilized by pacing-or exercise-induced ischemia may potentiate the effects of nifedipine, or that a direct biochemical effect of the drug not studied explicitly may persist for up to 15 minutes.
Nifedipine has been reported to normalize relaxations when it is prolonged by ischemia23-27; under nonischemic conditions, it prolongs relaxation.16r22 IC nifedipine reduced peak negative dP/dt, although the effect may have been partially antagonized by catecholamine release.28p2g At the higher dose, T was significantly prolonged; at the lower dose, the reduction of peak negative dP/dt was attributable to a fall in left ventricular peak systolic pressure.l7J8 Prolongation of diastole may reflect drug-induced slowing of calcium release in the perfused region, asynchronous contraction and subsequent prolonged relaxation.16J2 Under the nonischemic and eucalcemic conditions of this study, it is less likely that nifedipine improves relaxation by preventing intracellular calcium overload during systole, as suggested by recent studies of the effect of verapamil on chick embryo ventricular cells30
The present study confirms that the use of a parenteral formulation of nifedipine is safe, that IC nifedipine may be useful in the treatment of coronary spasm and that IV nifedipine may be useful in the treatment of hypertensive crises. In addition, the ability of IV nifedipine to lower systemic vascular resistance and increase cardiac output without depressing contractility suggests that it may be useful in the treatment of cardiac failure, particularly cardiac failure due to coronary artery disease. 
